Information Provided By:
Fly News Breaks for January 31, 2020
VRTX
Jan 31, 2020 | 05:35 EDT
Baird analyst Brian Skorney downgraded Vertex Pharmaceuticals to Neutral from Outperform with a price target of $230, up from $210.